|
OPEXA THERAPEUTICS NEWS
09/19/2008
Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin® for the Treatment of Multiple Sclerosis
Tovaxin Shows Favorable Annualized Relapse Rate and Excellent Safety Profile
09/11/2008
Top-Line Data from Opexa’s Phase IIb Tovaxin® Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis
Novel T-Cell Vaccine Being Evaluated as Patient-Specific Treatment for MS
09/03/2008
Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program
Collaboration to Identify Therapeutically Relevant Biomarkers and Offer Key Insight for Further Clinical Development of Tovaxin®
08/14/2008
Opexa Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
Conference Call Scheduled for August 19, 2008, at 4:00 p.m. Eastern Time
08/13/2008
Opexa Therapeutics Completes $3 Million Financing
Funding to Support Ongoing Clinical Development of Tovaxin®
07/22/2008
Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin® for Multiple Sclerosis
Annual treatments with patient specific vaccine appear beneficial
07/08/2008
Opexa’s Phase IIb Study of Tovaxin® Receives Positive Review
from Data Safety Monitoring Board
06/17/2008
Opexa Therapeutics Appoints Neil K. Warma President and CEO
06/16/2008
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at
the International Society for Stem Cell Research Annual Meeting
Insulin signaling pathways identified in monocyte-derived islets
06/12/2008
Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin® for Multiple Sclerosis
73% of patients remained relapse-free at two years
05/22/2008
Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the International Society of Cell Therapy Annual Meeting
05/14/2008
Opexa Therapeutics Schedules First Quarter Results Conference Call; May 21, 2008 at 4:00 p.m. Eastern Tim
05/13/2008
Opexa Therapeutics Reports First Quarter 2008 Financial Results and Updates on Tovaxin® Phase IIb Study
04/15/2008
Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting
03/26/2008
Opexa Therapeutics’ Form 10-K Report Audit Includes 'Going Concern' Qualific
03/24/2008
Opexa Therapeutics to Present at the Cambria Capital Investor Meeting
03/21/2008
Opexa Therapeutics Announces Retirement of CEO David McWilliams
Search Underway for Successor
03/18/2008
Opexa Therapeutics Reports Year End 2007 Financial Results
Conference Call Scheduled for March 25th at 4:00 p.m. Eastern Time
03/11/2008
Opexa Therapeutics Announces Completion of Mid Study Descriptive
Analysis on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
Data Safety Monitoring Board Recommends Continuing Trial as Scheduled
02/19/2008
Opexa Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Series E Warrant
02/13/2008
Opexa Therapeutics Announces the Pricing of Public Offering of Shares of Common Stock and Series E Warrant
11/16/2007
Opexa Therapeutics’ Amendment No.1 on Form 10-KSB/A Report Audit Includes 'Going Concern' Qualific
11/05/2007
Opexa Reports Third Quarter 2007 Financial Result
10/05/2007
Opexa Therapeutics to Present at the BIO Investor Forum 200
09/26/2007
Opexa Therapeutics Appoints Dr. Dawn McGuire, Prominent Neurologist, to Multiple Sclerosis Clinical Advisory Board
09/01/2007
For More Press Releases Please Visit www.opexatherapeutics.com
|
